Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly ...

Amram Kahn, MD, shares strategies for reconciling disparate clinical recommendations to optimize medication regimens for ...

Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors ASCO Guidelines provide ...

You will be redirected to our submission process. Pulmonary embolism (PE) presents significant risks when escalating to a high-risk state, demanding immediate and effective intervention. Over the ...

A new clinical classification scheme is presented, entitled “Acute Pulmonary Embolism Clinical Categories,” with 5 categories (A-E) and subcategories, ranging from low to high risk for adverse ...

MIAMI--(BUSINESS WIRE)--OpenEvidence now integrates National Comprehensive Cancer Network ® (NCCN ®) Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) directly in answers, grounding ...

OpenEvidence now integrates National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) directly in answers, grounding responses in the pinnacle ...

California-based medtech E2 (Endovascular Engineering) has raised $80 million in a series C funding round as it looks to commercialize its pulmonary embolism treatment. The Hēlo Thrombectomy Platform ...